<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Social</title>
	<atom:link href="http://www.tapanray.in/tag/social/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Accelerating Footfalls In Less Charted Pharma Marketing Frontiers</title>
		<link>http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=accelerating-footfalls-in-less-charted-pharma-marketing-frontiers</link>
		<comments>http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/#comments</comments>
		<pubDate>Mon, 27 Mar 2023 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[conferences]]></category>
		<category><![CDATA[continualtion]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[footfalls]]></category>
		<category><![CDATA[frontiers]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10755</guid>
		<description><![CDATA[Having experienced unprecedented disruptions, especially in the pharmaceutical and biopharmaceutical business, many global and local drug majors, are rethinking their marketing strategies. These have, no doubt, been prompted by the challenges of change, which are sometimes stark, but more often than &#8230; <a href="http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/accelerating-footfalls-in-less-charted-pharma-marketing-frontiers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Do Drug Companies Now Need More Focus On The 5th &#8220;P&#8221; Of Marketing?</title>
		<link>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing</link>
		<comments>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/#comments</comments>
		<pubDate>Mon, 07 Mar 2022 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[4 Ps]]></category>
		<category><![CDATA[5th P]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driving]]></category>
		<category><![CDATA[Get Z]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[marketing-mix]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10665</guid>
		<description><![CDATA[Astute marketers understand that over several decades, the much-known phraseology &#8211; ‘marketing mix’, has remained the bedrock of marketing a product or a service. The ‘Father of Modern Marketing’ - Philip Kotler defined this terminology as the &#8220;the set of controllable variables that &#8230; <a href="http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Restart Pharma Demand Generation Activities With Actionable Insight</title>
		<link>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=restart-pharma-demand-generation-activities-with-actionable-insight</link>
		<comments>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/#comments</comments>
		<pubDate>Mon, 01 Jun 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[activity]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Insishr]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10107</guid>
		<description><![CDATA[As the ‘Lockdown. 04’ in India passes by, a time comes to press the restart button of all business activities in the country, in a calibrated manner, though, keeping in mind, the Covid-19 cases is yet to find its peak &#8230; <a href="http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/restart-pharma-demand-generation-activities-with-actionable-insight/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Come Covid-19 Drug And Vaccine, Pharma Will Get Back To The Traditional Mode</title>
		<link>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode</link>
		<comments>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/#comments</comments>
		<pubDate>Mon, 18 May 2020 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[HiNI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[scientifically]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10084</guid>
		<description><![CDATA[‘Corona will remain a part of our lives for a long time. But at the same time, we cannot allow this to happen that our lives will be confined only around the corona. We would wear masks, follow two yards &#8230; <a href="http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/come-covid-19-drug-and-vaccine-pharma-will-get-back-to-the-traditional-mode/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Post Covid-19 Lockdown: Is Pharma Industry Ready?</title>
		<link>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=post-covid-19-lockdown-is-pharma-industry-ready</link>
		<comments>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/#comments</comments>
		<pubDate>Mon, 27 Apr 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer-centric]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herd-immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ready]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10033</guid>
		<description><![CDATA[It’s over a month now since national lockdown in India came into force to win the war against Covid-19. Many promises and apprehensions about whether or not Covid-19 will keep ravaging human life, continue surfacing. As it appears today, whatever &#8230; <a href="http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Acid Test For Excellence in Crisis Leadership</title>
		<link>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=acid-test-for-excellence-in-crisis-leadership</link>
		<comments>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/#comments</comments>
		<pubDate>Mon, 13 Apr 2020 00:07:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[21 day]]></category>
		<category><![CDATA[Acid]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Italy]]></category>
		<category><![CDATA[Juty]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Mask]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[PPE]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[turnaround]]></category>
		<category><![CDATA[United Staes]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9986</guid>
		<description><![CDATA[On April 12, 2020 – in the morning of the day 19 of the national lockdown, India’s total number of Coronavirus positive cases reached 8,504 with 289 deaths. The country&#8217;s trajectory is reportedly  steeper than most Asian peers, such as Singapore, Japan, and Indonesia. &#8230; <a href="http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/acid-test-for-excellence-in-crisis-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rebalancing Skill Sets In Pharma Sales And Marketing</title>
		<link>http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rebalancing-skill-sets-in-pharma-sales-and-marketing</link>
		<comments>http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/#comments</comments>
		<pubDate>Mon, 29 May 2017 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[automation. technology]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[natives]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rebalancing]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[soft]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8245</guid>
		<description><![CDATA[A disturbing trend against much needed more job creation across the world, has been well captured in a May 2016 MIT article. It concluded through several complex mathematical models that: “As more tasks performed by labor are being automated, concerns &#8230; <a href="http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rebalancing-skill-sets-in-pharma-sales-and-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Recomposing Notes of Pharma Marketing Playbook</title>
		<link>http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=recomposing-notes-of-pharma-marketing-playbook</link>
		<comments>http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/#comments</comments>
		<pubDate>Mon, 20 Jun 2016 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[circle]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[logo]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Notes]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Playbook]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Recomposing]]></category>
		<category><![CDATA[representative]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[surrogate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vicious]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7680</guid>
		<description><![CDATA[The global management guru Peter Drucker, in one of his management classics &#8211; “The Practice of Management”, published in 1954, that created the discipline of modern management practices, had underscored the following:  “As the core purpose of any business is to &#8230; <a href="http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Highest Billionaire Wealth Concentration, India Tops Malnutrition Chart in South Asia: &#8220;What Future Do You Want?&#8221;</title>
		<link>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want</link>
		<comments>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/#comments</comments>
		<pubDate>Mon, 26 Jan 2015 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amit]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Billionaire]]></category>
		<category><![CDATA[BJP]]></category>
		<category><![CDATA[Chart]]></category>
		<category><![CDATA[Concentration]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Davos]]></category>
		<category><![CDATA[demographic]]></category>
		<category><![CDATA[dividend]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequality]]></category>
		<category><![CDATA[Justice Louis Brandeis]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Shah]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tops]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UNICEF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Wealth]]></category>
		<category><![CDATA[WEF]]></category>
		<category><![CDATA[What Future Do You Want]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6352</guid>
		<description><![CDATA[Two recent global research reports, though on different spheres, place India at the top of the respective blocks. However, the take away messages that the studies offer are indeed poles apart in qualitative terms and worth pondering over collectively. On &#8230; <a href="http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drug Pricing: Relevance To R&amp;D Investments</title>
		<link>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drug-pricing-relevance-to-rd-investments</link>
		<comments>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/#comments</comments>
		<pubDate>Mon, 18 Aug 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevance R&D]]></category>
		<category><![CDATA[smarter]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5766</guid>
		<description><![CDATA[The costs of most of the new life saving drugs, used in the treatment of dreaded diseases such as cancer, have now started going north at a brisk pace, more than ever before. From the global pharma industry perspective, the &#8230; <a href="http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
